BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal

  Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds.

  December 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• Pharm Country

  Dr. Reddy’s Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market

  Dr. Reddy’s Melphalan Hydrochloride for Injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.

  December 26, 2017

   · 

  3 min read
• Drug Development

  DelMar Pharma Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

  This Fast Track status applies to two ongoing clinical trials sponsored by DelMar Pharma to evaluate VAL-083 as a potential treatment for rGBM.

  December 26, 2017

   · 

  6 min read
• FDA

  Alexion Release: Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)

  Soliris is the first and only complement inhibitor approved in Japan as a treatment for these patients.

  December 26, 2017

   · 

  14 min read
• Eone-Diagnomics Genome Center (EDGC) Attracts Investment from Lock & Lock Chairman, Kim Joon-il

  Chairman Kim founded Lock & Lock in 1978, and it has since grown into a global kitchenware company, exporting to more than 100 countries around the world.

  December 26, 2017

   · 

  2 min read
• Lone Star Bio

  Clarity Science Study Shows Discontinuation of Opioids and Improvement in Chronic Pain After Topical Analgesic Treatment

  Overall results, published today in the Journal of Postgraduate Medicine show that approximately 50% of patients taking opioids and prescribed topical analgesics for their pain discontinued use of their opioid medication after 3- or 6-months of treatment.

  December 26, 2017

   · 

  4 min read
• Tesseract Medical Research Launches New Products at Natural Partners, Featuring New Patent-Pending Delivery Science

  Natural Partners is proud to feature the latest products from Tesseract Medical Research, TetraCumin SR and TetraCumin QR.

  December 26, 2017

   · 

  3 min read
• Business

  Dr. Marcus Schabacker Named ECRI Institute’s New CEO and President

  ECRI Institute’s Board of Trustees announces the appointment of Marcus Schabacker, MD, PhD, as the new Chief Executive Officer and President.

  December 26, 2017

   · 

  3 min read